Connect with us

INDUSTRIAL HEMP

AbbVie Inc (NYSE:ABBV) And Harpoon Therapeutics Collaborates For Immuno-Oncology Research

Published

on

AbbVie Inc (NYSE:ABBV) and Harpoon Therapeutics have entered into an immuno-oncology research collaboration. The objective of the deal is to incorporate Harpoon’s TriTAC™ platform with former’s research-stage immuno-oncology targets to advance novel cancer therapeutics.

The details

Under the terms of the deal, Harpoon will engineer TriTAC molecules aimed against selected cancer targets utilizing its proprietary platform, assess the molecules for pharmacologic properties, and offer AbbVie the right to follow further commercialization and development of these molecules. Financial terms were not revealed. Jerry McMahon, Ph.D., the CEO of Harpoon Therapeutics, expressed that this deal is the first for them and presents the high level of industry interest in premium platform technologies.

They are thrilled about associating with AbbVie to help generate unique T-cell engagers for the cure of cancer depending on the combination of T-cell receptors with TriTACs. Tom Hudson, M.D., VP of oncology early discovery & development at AbbVie stated that T-cell therapies showcase the next wave of advancement in cancer treatment. Harpoon’s technology provides the potential for an innovative approach to engage the immune system via company’s investigational therapies in advancement.

Harpoon Therapeutics is an immuno-oncology firm established by Patrick Baeuerle, Ph.D., a leader in the advancement of T-cell engaging treatments, and MPM Capital. The firm is focused on the development and discovery of unique T-cell engaging biologics for the cure of cancer and other ailments. It advanced an innovative T-cell recruiting drug discovery platform named TriTAC™ to release the targeted cell-killing properties of a subject’s own immune system via T-cell activation.

This plan is being enhanced to extend serum exposure and penetrate tissues, and has the prospect to resolve a broad range of cancers and immunologic diseases. HPN424, a PSMA)-targeting TriTAC™ biologic, is in advancement for the treatment of prostate cancer and is anticipated to enter a clinical study in 2018.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement